212 related articles for article (PubMed ID: 18165147)
1. Modeling therapy resistance in genetically engineered mouse cancer models.
Rottenberg S; Jonkers J
Drug Resist Updat; 2008; 11(1-2):51-60. PubMed ID: 18165147
[TBL] [Abstract][Full Text] [Related]
2. The mighty mouse: genetically engineered mouse models in cancer drug development.
Sharpless NE; Depinho RA
Nat Rev Drug Discov; 2006 Sep; 5(9):741-54. PubMed ID: 16915232
[TBL] [Abstract][Full Text] [Related]
3. Studying drug resistance using genetically engineered mouse models for breast cancer.
Rottenberg S; Pajic M; Jonkers J
Methods Mol Biol; 2010; 596():33-45. PubMed ID: 19949919
[TBL] [Abstract][Full Text] [Related]
4. On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing.
Man S; Munoz R; Kerbel RS
Cancer Metastasis Rev; 2007 Dec; 26(3-4):737-47. PubMed ID: 17846863
[TBL] [Abstract][Full Text] [Related]
5. Medicine. Building better mouse models for studying cancer.
Marx J
Science; 2003 Mar; 299(5615):1972-5. PubMed ID: 12663895
[No Abstract] [Full Text] [Related]
6. Advances in molecular carcinogenesis: current and future use of mouse models to screen and validate molecularly targeted anticancer drugs.
Frijhoff AF; Conti CJ; Senderowicz AM
Mol Carcinog; 2004 Apr; 39(4):183-94. PubMed ID: 15057870
[TBL] [Abstract][Full Text] [Related]
7. Overcoming drug resistance in patients with metastatic breast cancer.
Wong ST; Goodin S
Pharmacotherapy; 2009 Aug; 29(8):954-65. PubMed ID: 19637949
[TBL] [Abstract][Full Text] [Related]
8. Spontaneous and genetically engineered animal models; use in preclinical cancer drug development.
Hansen K; Khanna C
Eur J Cancer; 2004 Apr; 40(6):858-80. PubMed ID: 15120042
[TBL] [Abstract][Full Text] [Related]
9. Targeted anticancer therapies: mouse models help uncover the mechanisms of tumor escape.
van Amerongen R; Berns A
Cancer Cell; 2008 Jan; 13(1):5-7. PubMed ID: 18167334
[TBL] [Abstract][Full Text] [Related]
10. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer.
Pajic M; Iyer JK; Kersbergen A; van der Burg E; Nygren AO; Jonkers J; Borst P; Rottenberg S
Cancer Res; 2009 Aug; 69(16):6396-404. PubMed ID: 19654309
[TBL] [Abstract][Full Text] [Related]
11. Practices and pitfalls of mouse cancer models in drug discovery.
Kung AL
Adv Cancer Res; 2007; 96():191-212. PubMed ID: 17161681
[TBL] [Abstract][Full Text] [Related]
12. Transgenic mouse models for the prevention of breast cancer.
Shen Q; Brown PH
Mutat Res; 2005 Aug; 576(1-2):93-110. PubMed ID: 15888345
[TBL] [Abstract][Full Text] [Related]
13. The promise of genetically engineered mice for cancer prevention studies.
Green JE; Hudson T
Nat Rev Cancer; 2005 Mar; 5(3):184-98. PubMed ID: 15738982
[TBL] [Abstract][Full Text] [Related]
14. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
15. From mice to men: GEMMs as trial patients for new NSCLC therapies.
Hayes SA; Hudson AL; Clarke SJ; Molloy MP; Howell VM
Semin Cell Dev Biol; 2014 Mar; 27():118-27. PubMed ID: 24718320
[TBL] [Abstract][Full Text] [Related]
16. The origins of oncomice: a history of the first transgenic mice genetically engineered to develop cancer.
Hanahan D; Wagner EF; Palmiter RD
Genes Dev; 2007 Sep; 21(18):2258-70. PubMed ID: 17875663
[TBL] [Abstract][Full Text] [Related]
17. Probing p53 biological functions through the use of genetically engineered mouse models.
Attardi LD; Donehower LA
Mutat Res; 2005 Aug; 576(1-2):4-21. PubMed ID: 16038709
[TBL] [Abstract][Full Text] [Related]
18. Using genetically engineered mouse models to validate candidate cancer genes and test new therapeutic approaches.
van Miltenburg MH; Jonkers J
Curr Opin Genet Dev; 2012 Feb; 22(1):21-7. PubMed ID: 22321988
[TBL] [Abstract][Full Text] [Related]
19. The Mouse Tumor Biology Database: integrated access to mouse cancer biology data.
Krupke D; Näf D; Vincent M; Allio T; Mikaelian I; Sundberg J; Bult C; Eppig J
Exp Lung Res; 2005 Mar; 31(2):259-70. PubMed ID: 15824024
[TBL] [Abstract][Full Text] [Related]
20. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
